Sector Update: Health Care Stocks Higher Premarket Monday

MT Newswires Live

Yesterday

Health care stocks were higher premarket Monday, with the Health Care Select Sector SPDR Fund (XLV) edging 0.03% higher and the iShares Biotechnology ETF (IBB) up 0.3%.

Arcus Biosciences (RCUS) stock was up nearly 9% after the company said a phase 2 study on various combinations of domvanalimab plus zimberelimab with chemotherapy achieved a 26.7-month median overall survival in patients with advanced stomach and esophageal cancer, including tumors not removable by surgery, with a 50% two-year survival rate.

Precigen (PGEN) shares were up nearly 6% after the company said follow-up data from a clinical study showed durable outcomes in 83% of adult recurrent respiratory papillomatosis patients treated with its drug Papzimeos.

Tvardi Therapeutics (TVRD) shares were down more than 85% after the company said a phase 2 clinical trial of its drug TTI-101 as a potential treatment for idiopathic pulmonary fibrosis failed to meet its goals.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2575017244"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575017244\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575017244?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-13 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575017244","market":"fut","top_or_hot":-1,"title":"Sector Update: Health Care Stocks Higher Premarket Monday","media":"MT Newswires Live","content":"<html><body><p> Health care stocks were higher premarket Monday, with the Health Care Select Sector SPDR Fund (XLV) edging 0.03% higher and the <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Biotechnology ETF (IBB) up 0.3%.</p><p><a href=\"https://laohu8.com/S/RCUS\">Arcus Biosciences</a> (RCUS) stock was up nearly 9% after the company said a phase 2 study on various combinations of domvanalimab plus zimberelimab with chemotherapy achieved a 26.7-month median overall survival in patients with advanced stomach and esophageal cancer, including tumors not removable by surgery, with a 50% two-year survival rate.</p><p><a href=\"https://laohu8.com/S/PGEN\">Precigen</a> (PGEN) shares were up nearly 6% after the company said follow-up data from a clinical study showed durable outcomes in 83% of adult recurrent respiratory papillomatosis patients treated with its drug Papzimeos.</p><p>Tvardi <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TVRD) shares were down more than 85% after the company said a phase 2 clinical trial of its drug TTI-101 as a potential treatment for idiopathic pulmonary fibrosis failed to meet its goals.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sector Update: Health Care Stocks Higher Premarket Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSector Update: Health Care Stocks Higher Premarket Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-13 21:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Health care stocks were higher premarket Monday, with the Health Care Select Sector SPDR Fund (XLV) edging 0.03% higher and the <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Biotechnology ETF (IBB) up 0.3%.</p><p><a href=\"https://laohu8.com/S/RCUS\">Arcus Biosciences</a> (RCUS) stock was up nearly 9% after the company said a phase 2 study on various combinations of domvanalimab plus zimberelimab with chemotherapy achieved a 26.7-month median overall survival in patients with advanced stomach and esophageal cancer, including tumors not removable by surgery, with a 50% two-year survival rate.</p><p><a href=\"https://laohu8.com/S/PGEN\">Precigen</a> (PGEN) shares were up nearly 6% after the company said follow-up data from a clinical study showed durable outcomes in 83% of adult recurrent respiratory papillomatosis patients treated with its drug Papzimeos.</p><p>Tvardi <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TVRD) shares were down more than 85% after the company said a phase 2 clinical trial of its drug TTI-101 as a potential treatment for idiopathic pulmonary fibrosis failed to meet its goals.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2575017244","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575017244","pubTimestamp":1760361604,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Health care stocks were higher premarket Monday, with the Health Care Select Sector SPDR Fund  edging 0.03% higher and the iShares Biotechnology ETF  up 0.3%.Arcus Biosciences  stock was up nearly 9% after the company said a phase 2 study on various combinations of domvanalimab plus zimberelimab with chemotherapy achieved a 26.7-month median overall survival in patients with advanced stomach and esophageal cancer, including tumors not removable by surgery, with a 50% two-year survival rate.Precigen  shares were up nearly 6% after the company said follow-up data from a clinical study showed durable outcomes in 83% of adult recurrent respiratory papillomatosis patients treated with its drug Papzimeos.Tvardi Therapeutics  shares were down more than 85% after the company said a phase 2 clinical trial of its drug TTI-101 as a potential treatment for idiopathic pulmonary fibrosis failed to meet its goals.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","XBI":"SPDR S&P Biotech ETF","IBB":"生物科技指数ETF-iShares Nasdaq","TVRD":"Tvardi Therapeutics Inc","BK4139":"生物科技","RCUS":"Arcus Biosciences Inc.","PGEN":"Precigen","BK4581":"高盛持仓","LABU":"三倍做多标普生物-Direxion","BK4007":"制药","XLV":"健康照护类股ETF-SPDR","BK4588":"碎股"},"translate_title":"行业更新：医疗保健股周一盘前走高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBB":1,"PGEN":1,"RCUS":1,"TVRD":1,"XLV":1,"LABU":0.6,"XBI":0.6},"content_text":"Health care stocks were higher premarket Monday, with the Health Care Select Sector SPDR Fund (XLV) edging 0.03% higher and the iShares Biotechnology ETF (IBB) up 0.3%.Arcus Biosciences (RCUS) stock was up nearly 9% after the company said a phase 2 study on various combinations of domvanalimab plus zimberelimab with chemotherapy achieved a 26.7-month median overall survival in patients with advanced stomach and esophageal cancer, including tumors not removable by surgery, with a 50% two-year survival rate.Precigen (PGEN) shares were up nearly 6% after the company said follow-up data from a clinical study showed durable outcomes in 83% of adult recurrent respiratory papillomatosis patients treated with its drug Papzimeos.Tvardi Therapeutics (TVRD) shares were down more than 85% after the company said a phase 2 clinical trial of its drug TTI-101 as a potential treatment for idiopathic pulmonary fibrosis failed to meet its goals.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}